MedTrace Logo

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

NCT01160705 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2020-11-17

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This clinical trial is studying blood samples in predicting how patients with prostate cancer will respond to treatment with docetaxel.

Conditions

Interventions

DRUG

docetaxel

GENETIC

RNA analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

circulating tumor cell analysis

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • Cancer Trials Ireland

    lead NETWORK

Principal Investigators

  • Ray McDermott, MD · Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2017-09-19

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01160705 on ClinicalTrials.gov